Data

Presenter

Title

Journal

Year

Vol

Page

J Clin Oncol.

2022

40(10)

1091-1101

Positron Emission tomography-Driven Srategy in Advanced Hodgikin Lymphoma:Prolonged Follow-Up of the AHL2011 Phase Ⅲ⻄村
2022/4/5

Lymphoma Positron Emission tomography-Driven Srategy in Advanced Hodgikin Lymphoma:Prolonged Follow-Up of the AHL2011
Phase Ⅲ Lymphoma Study Association Study加藤

Autologous transplant vs chimeric antigen receptor-T-Cell therapy for relapsed DLBCL in partial remission

Blood

2022

139(9)

1330-1339

勝岡

Gain of function mutation in RPA1 cause a syndrome with short telomeres and somatic genetic rescue

Blood

2022

139(7)

1039-1051

今泉

Phase 1 /dose expansion trial of brentuximab vedotin and lenalidomide in relapse or refractory diffuse large B-cell lymphoma

Blood

2022

139(13)

1999-2010

Cell

2022

185(4)

585-6022022/4/12

クリクラ学⽣ Magnesium sensing via LFA-1 regulates CD8+ T cell effector function
2022/4/19
安東

The day 100 score predicts moderate to severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation

Blood Adv

2022

6(7)

2309-2318

⼭⽥

PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma

Blood2016

128(10)1374-1381

⽷永YBX1 mediates translation of oncogenic transcripts to control cell competition in AML

Leukemia

2022

36(2)

426-437

蓬莱

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia

N Eng J Med

2022

386(16)1519-1531

佐藤

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

N Eng J Med

2022

384(3)

705-716

⼀瀬Analysis of distinct SF3B1 hotspot mutations in relation to clinical phenotypes and response to study myeloid neoplasia

Leuk Lymphoma

2021

62(3)

735-738

宮﨑TRAF6 functions as a tumor suppressor in myeloid malignancy by directly targeting MYC oncogenic activity

Cell stem cell

2022

29(2)

298-314Br J Haematol2022

196(6)

e71-e74

Nat Cancer

2022

3(5)

552-564

Nat Med

2022

28(4)

735-742

Haematologica

2021

106(1)

56-63

Blood

2022

139(2)

177-187

J Clin Oncol.

2022

40(25)

2889-2900

Cancer Cell

2022

40(5)

494-5082022/4/26

2022/5/10

2022/5/17

クリクラ学⽣2022/5/24

Venetoclax and Hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed
acute myeloid leukemia

⻑井Immune responses against SARS-CiV2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study

古本

第62回リンパ・網内系学会 予⾏演習加藤Axicabtagene cioleucel as first-line therapy in high-risk large B cell lymphoma :the phase 2 ZUMA-12 trial

2022/5/31

勝岡
2022/6/1
今泉⻄村
2022/6/14

Measurable residual disease monitoring provides insufficient lead-time to prevent morphological relapse in the majority of patients withcore-binding factor acute myeloid leukemia.
The CLL12 trial :ibrutinib vs placebo in teatment-naive , early-stage chronic lymphocytic leukemia.
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact ofLenalidomide Maintenance and Molecular Risk

安東

Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia

松本Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA studyBlood2022

139(15)2338-2346

⽷永Functional mapping of PHF6 complexes in chromatin remodeling, replication dynamics, and DNA repair

Blood

2022

139(23)3418-3429

⼀瀬

R-loop proximity proteomics identifies a role of DDX41 in transcription-associated genomic instability

Nat Commun

2021

12(1)

7314

佐藤

Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis

J Clin Oncol.

2022

40(16)

1783-1794

2022/6/21

2022/6/28